FTSE 100 Falls as US-Iran Conflict Drives Oil Prices Higher 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Oil Prices Rise as US-Iran Conflict Threatens Middle East Supply 
Gold Prices Hold Near $4,500 as Fed Rate Hike Bets Ease 
US Strikes Iran IRGC Targets as Conflict Escalates 
Asian Currencies Rise as Yen Surges on BOJ Rate Hike Bets 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
OpenAI Rejects Apple Trade Secret Theft Claims 
China Services PMI Beats Forecasts as Domestic Demand Improves 
Australia Trade Surplus Beats Forecasts in July as Exports Fall 
Oil Prices Surge as U.S.-Iran Conflict Threatens Hormuz Supply 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Yen Extends Gains as BOJ Rate Hike Bets Rise 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Add as a preferred source on Google
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
